1. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?

    Alzheimer's & Dementia 10(6):853 (2014) PMID 25458309

    Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The Nationa...
  2. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?

    Alzheimer's & Dementia 10(6):853 (2014) PMID 25458309

    Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The Nationa...
  3. Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?

    Alzheimer's & Dementia 10(6):853 (2014) PMID 25458309

    Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The Nationa...
  4. Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?

    Alzheimer's & Dementia 10(6):853 (2014) PMID 25458309

    Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The Nationa...
  5. Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?

    Alzheimer's & Dementia 10(6):853 (2014)

    Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. T...
  6. Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany.

    Quality of Life Research 23(6):1813 (2014) PMID 24448684

    To estimate the relative importance that Alzheimer's disease (AD) caregivers in the United States and Germany place on preserving patients' ability to perform activities of daily living. US and German residents providing care for a person with AD completed an online preference survey. Each respo...
  7. Assessing Cognition and Function in Alzheimer's Disease Clinical Trials: Do We Have the Right Tools?

    Alzheimer's & Dementia (2014)

    Several lines of evidence from Alzheimer’s disease (AD) research continue to support the notion that the biological changes associated with Alzheimer’s disease are occurring possibly several decades before an individual will experience the cognitive and functional changes associated wi...
  8. Effect of amyloid imaging on diagnosis and management of patients with cognitive decline: Impact of appropriate use criteria

    Alzheimer's & Dementia 10(4):P248 (2014)

  9. EFFECT OF AMYLOID IMAGING ON DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH COGNITIVE DECLINE: IMPACT OF APPROPRIATE USE CRITERIA

    Alzheimer's & Dementia 10(4):P248 (2014)

  10. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  11. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  12. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  13. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  14. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  15. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  16. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  17. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  18. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  19. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...
  20. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):322 (2014) PMID 24450891 PMCID PMC4159618

    Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 car...